Patent · US Active

Acylated exendin-4 compounds

US9012398B2 · kind B2 · utility

4Cited by
1References
18Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 1, 2012
Grant dateApr 21, 2015
Priority date
Expiry dateOct 10, 2032

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K38/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This invention provides Exendin-4 compounds derivatized at a lysine 14 residue to give an acylated lysine, pharmaceutical compositions comprising such compounds, and the use of such compositions for treating diabetes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.